Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

Farah M. Shurrab 1, Duwa W. Al-Sadeq 1,2, Haissam Abou-Saleh 1,3, Nader Al-Dewik 4, Amira E. Elsharafi 5, Fatima M. Hamaydeh 5, Bushra Y. Abo Halawa 3, Tala M. Jamaeddin 5, Huda M. Abdul Hameed 5, Parveen B. Nizamuddin 1, Fatimah Humaira Amanullah 1, Hanin I. Daas 6,7,8,9, and Gheyath K. Nasrallah 1,5,9

Abstract: The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAb) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAb in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAb than the naïve BNT162b2 (n = 358) group. The PI-vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAb levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (<30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAb response than the BNT162b2 vaccine, and the PI group generated the highest level of NAb response regardless of the type of vaccine.

Keywords: neutralizing antibodies; Pfizer-BNT162b2; Moderna-mRNA-1273; SARS-CoV-2; vaccine

1. Introduction

Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic, causing significant widespread morbidity and mortality. The severe acute respiratory syndrome...
coronavirus-2 (SARS-CoV-2) has infected over 100 million individuals, with more than five million deaths [1]. The current COVID-19 epidemiological status in Qatar at the time of this study (3 to 17 January 2022) is as follows: 299,242 confirmed cases, 626 deaths, and 5,447,278 vaccine doses have been administered (WHO) [2]. The total population of Qatar is ~2.6 million. As of today, 84.5% of the Qatari population has received at least two doses of the vaccines (either BNT162b2 or mRNA-1273) and around 10% of the population has received the third dose.

The COVID-19 pandemic has launched an intensive effort worldwide to develop efficient vaccines. As a result, different technologies have been used to develop effective vaccines, including mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), viral vector vaccines such as ChAdOx1 (Oxford/AstraZeneca), and inactivated vaccines such as Sinovac and Sinopharm [3]. BNT162b2 and mRNA-1273, obtained Emergency Use Listing (EUL) from WHO and have demonstrated a high degree of protection against the COVID-19 illness [4,5]. These vaccines induce antibodies to the SARS-CoV-2 spike protein (S-protein), including NAbs against the receptor-binding domain (RBD) of the S-protein (S-RBD) [6]. To have a general idea about the immune response to the aforementioned vaccines, we recently analyzed the binding antibody (total antibodies, IgG, and IgA) response to anti-SARS-CoV-2 antibodies to S-RBD [7]. Because it is evident now that the level of vaccine-induced NAbs response correlates better with the degree of protection than the binding antibodies [8–10], here, we further investigated the NAbs response generated after vaccination with the BNT162b2 or the mRNA-1273 vaccines in naïve and previously infected (PI) groups.

2. Material and Methods

2.1. Ethical Approval and Sample Collection

Randomized participants who received two BNT162b2 or mRNA-1273 vaccine doses were eligible for inclusion. A total of 468 blood samples were collected from staff and students at Qatar University, the national university in Qatar, with different age groups and nationalities. Peripheral blood was collected 1–26 weeks (BNT162b2 median = 9, mRNA-1273 median = 6, PI median = 9) following the administration of the second dose of the vaccine. Participants were naïve or PI with SARS-CoV-2. The median duration between previous infection and vaccination with the second dose was 22 weeks. In addition, demographic information, including the previous history of infection, was collected through a self-administered questionnaire. The study was reviewed and approved by the Institutional Review Board at Qatar University (QU-IRB 1537-FBA/21). Plasma was separated from venous whole blood collection and stored at −80 °C until the immunoassays.

2.2. Serology Testing

NAbs testing was carried out using the CL-900i® automated analyzer from Mindray Bio-Medical Electronics. The performance CL-900i® was previously validated [11–13]. The CL-900i® NAbs assay is a chemiluminescence immunoassay, where NAbs in the sample compete with ACE2-ALP conjugate for the binding sites of SARS-COV-2 S-RBD immobilized in the paramagnetic microparticles. According to the WHO standards, the conversion factor of this assay is 1 AU = 3.31 IU/mL, and the reference range is from 10 to 400 AU/mL (Ref.: SARS-CoV-2 Neutralizing Antibody 121, Mindray, China). All samples with readings higher than the reference range were diluted with phosphate-buffered saline (PBS). In addition, all samples were tested using the Architect automated chemiluminescent assay (Abbott Laboratories, Abbott Park, IL, USA) to detect anti-N SARS-CoV-2 IgG antibodies; the test was carried out according to the manufacturer’s instructions [13]. Therefore, PI status was classified as anti-N IgG positive results and/or having confirmed positive RT-PCR results collected from the questionnaire.
2.3. Statistical Analysis

Data were analyzed using GraphPad Prism 9.2.0. (San Diego, CA, USA). D’Agostino–Pearson’s test for normal distribution was performed, followed by a one-way ANOVA test (Kruskal–Wallis with Dunn’s multiple comparisons). The results in the graphs were plotted as mean values with the standard deviation (SD), and p values < 0.05 were considered statistically significant. In all graphs, significance is marked as * if $p \leq 0.05$, ** if $p \leq 0.01$, and *** if $p \leq 0.001$.

3. Results

3.1. Participant Characteristic

The participants’ characteristics are described in Table 1. In total, 468 naïve mRNA-vaccinated and PI vaccinated volunteers participated in this study. Of these, 358 were naïve BNT162b2-vaccinated, 68 were naïve mRNA-1273-vaccinated, and 42 were PI (34 with BNT162b2 and eight with mRNA-1273) vaccinated participants.

Table 1. Demographic characteristics of the study sample ($n = 468$).

| Characteristic | BNT162b2 N (%) | mRNA-1273 N (%) |
|----------------|----------------|-----------------|
| Gender         |                |                 |
| Male           | Naïve 170 (47.5) | PI 10 (29.4) | Naïve 27 (39.7) | PI 3 (37.5) |
| Female         | 175 (48.9)      | 15 (44.1)      | 41 (60.3)       | 5 (62.5)    |
| Unknown        | 13 (3.6)        | 9 (26.4)       | -               | -           |
| Total          | 358             | 34             | 68              | 8           |
| Age (years)    |                |                 |
| >30            | 119 (33.2)      | 15 (44.1)      | 41 (60.3)       | 3 (37.5)    |
| 30–50          | 177 (49.4)      | 17 (50)        | 25 (36.8)       | 5 (62.5)    |
| >50            | 53 (14.8)       | 2 (5.8)        | 2 (2.9)         | -           |
| Unknown        | 9 (2.5)         | -              | -               | -           |
| Total          | 358             | 34             | 68              | 8           |

3.2. Neutralizing Antibody Response Assessment

All naïve mRNA-1273- and PI vaccinated groups had a 100% positive NAb response, whereas the response in the naïve BNT162b2-vaccinated group was 99.7%. The mean levels were $1.8 \times 10^3$ IU/mL (95% CI: 1.2–2.3 $\times 10^3$) for the naïve BNT162b2 group, $3.2 \times 10^3$ IU/mL (95% CI: 2.2–4.2 $\times 10^3$) for the naïve mRNA-1273 group, and $4.7 \times 10^3$ IU/mL (95% CI: 3.1–6.1 $\times 10^3$) for the PI group. The naïve mRNA-1273 vaccinated group generated a significantly higher level of NAb than the naïve BNT162b2 group (~2-fold, $p \leq 0.001$). The PI vaccinated group generated significantly higher NAb levels than the naïve BNT162b2 (~3-fold; $p \leq 0.001$). However, no significant difference was observed between the PI vaccinated group and the naïve mRNA-1273 group ($p = 0.7718$) (Figure 1A).
Vaccines 2022, 10, 191

Figure 1. (A) NAb levels (IU/mL) in mRNA vaccinated participants 1–26 weeks after receiving two doses, and participants with prior infection and two doses of the vaccine. (B) NAb levels (IU/mL) in BNT162b2-vaccinated participants according to age groups. The tests were performed using the automated analyzer Mindray Cl-900i. Asterisks on graphs denote * \( p \leq 0.05 \), ** \( p \leq 0.01 \), and *** \( p \leq 0.001 \); ns \( p > 0.05 \).

3.3. Age Effect on Neutralizing Antibody Response

Samples from the naïve BNT16b2-vaccinated participants (\( n = 349 \)) were categorized into different age groups: <30, 30–50, and >50 years old. The median age in each group was 22 (interquartile range (IQR): 21–26 years), 40 (IQR: 35–45 years), and 56 (IQR: 53–61 years) years, respectively. Each group’s mean NAb levels was 1.6 \( \times 10^3 \) IU/mL (95% CI: 1.3–1.9 \( \times 10^3 \)), 1.8 \( \times 10^3 \) IU/mL (95% CI: 7.7 \( \times 10^2 \)–2.8 \( \times 10^3 \)), and 2.0 \( \times 10^3 \) IU/mL (95% CI: 3.3 \( \times 10^2 \)–3.6 \( \times 10^3 \)), respectively. The older age groups produced a significantly higher levels of antibodies than the young age group (<30) (\( p = 0.0007 \)) (Figure 1B).

4. Discussion

Both PI and naïve vaccinated individuals showed robust immune responses to vaccination. However, this response appeared to be significantly higher in PI individuals, especially when compared with the naïve BNT162b2 group (Figure 1A). Our data are in concordance with previously published reports [14–16]. The acquired immunity from infection is boosted by vaccination. Memory B cells are likely responsible for providing a robust, immediate recall of high NAbs in PI individuals [17]. However, we noticed that some naïve vaccinated individuals could have a high level of NAbs response against SARS-CoV-2 (Figure 1A, BNT162b2-vaccinated group). The highest level of NAbs reached 8.2 \( \times 10^4 \) IU/mL, which a naïve BNT162b2-vaccinated individual generated. This robust immunity could be due to a particular genetic makeup or prior undetected asymptomatic infection. A recent computational study indicated that a set of major histocompatibility complex (MHC) genes, which are essential for the adaptive immune response, help to regulate the strength and durability of NAbs to SARS-CoV-2 [18].

Different mRNA vaccine products also resulted in different NAb responses. For instance, the level of NAbs evoked in the naïve mRNA-1273 group was significantly higher compared with the BNT162b2 group. These results are consistent with Tyner et al., who demonstrated that the mRNA-1273 vaccine generated higher NAbs titers when measured using a pseudovirus neutralization assay [19]. This can be explained by the fact that different vaccine formulations, dose contents, and intervals between doses may contribute to
the varying levels of NAb production between mRNA-1273 and BNT162b [20]. Although there was a twofold difference in NAb levels between mRNA-1273 and BNT162b post-vaccination, both mRNA vaccines showed high comparable efficacy against SARS-CoV-2 infection [4,5]. The wide interval (1–26 weeks) of sample collection between participants could have influence our results. However, we believe that this should have a minimal effect, as previous studies have shown that antibody levels start to decline 13–26 weeks after receiving the second dose [15,21,22].

The response of antibody levels to vaccination declined with age [23]. However, our serologic results showed an increasing trend with age. A previous study showed a minimal effect of age on antibody responses after vaccination [24]. This could be explained by the fact that BNT162b2 induces a high immune response, especially after two doses. Therefore, it elicited high NAb levels regardless of age. According to Jalkanen et al., the level of antibodies was significantly lower in elderly individuals (>50 years) compared with younger ones after receiving the first dose of BNT162b2. Nevertheless, this difference diminished upon receiving the second dose [24,25]. The observed increasing trend in our results can be explained by the higher frequency of SARS-CoV-2 spike-specific memory B cells’ response in the elderly group after receiving the second dose [26].

This study has some limitations. The immune response after the first dose needs further investigation, especially in the PI group. In addition, the kinetics and longevity of these NAb levels should be studied in the future. Lastly, although NAb were proven to correlate with protection [8], the minimum required levels of NAb to provide protection are not yet determined. Additionally, further investigation of the memory B and T cells’ responses after vaccination is needed. That is, it has been reported that vaccinated individuals may have continued protection against the diseases as a result of durable memory B and T cells [27].

5. Conclusions
In conclusion, our results showed that PI individuals generated higher NAb levels compared with naïve vaccinated participants after receiving two doses of the mRNA vaccine. However, although both vaccines showed an excellent NAb response against SARS-CoV-2, it is too early to make any firm conclusions based on these findings with implications for public health vaccine policy.

Author Contributions: Participant recruitment and demographic data collection: F.M.S., D.W.A.-S., A.E.E., F.M.H., B.Y.A.H., T.M.J., H.M.A.H., F.H.A. and H.I.D. Laboratory testing: F.M.S., D.W.A.-S., A.E.E., F.M.H., B.Y.A.H., T.M.J., H.M.A.H., P.B.N. and F.H.A. Supervision: H.A.-S. and G.K.N. First draft writing: F.M.S., D.W.A.-S. and G.K.N. Review and editing: L.J.A.-R. and G.K.N. Funding: G.K.N., L.J.A.-R., H.A.-S. and N.A.-D. All authors have read and agreed to the published version of the manuscript.

Funding: This work was made possible by grant number UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and was reviewed and approved by the Institutional Review Board at Qatar University (QU-IRB 1537-FBA/21).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study before collecting samples.

Data Availability Statement: Derived data supporting the findings of this study are available from the corresponding author upon request.

Conflicts of Interest: The authors would like to declare that the NAb testing kits were received (free of charge) from Mindray as in-kind support for G.K.N.
References

1. Johns Hopkins Coronavirus Resource Center. COVID-19 Map. Available online: https://coronavirus.jhu.edu/map.html (accessed on 16 September 2021).
2. WHO. Available online: https://covid19.who.int/region/emro/country/qa (accessed on 18 January 2022).
3. Yap, C.; Ali, A.; Prabhakar, A.; Prabhakar, A.; Pal, A.; Lim, Y.Y.; Kakodkar, P. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Ther. Adv. Vaccines Immunother. 2021, 9, 25151355211059791. [CrossRef]
4. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [CrossRef]
5. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Curtman, A.; Lockhart, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [CrossRef] [PubMed]
6. Krammer, F. SARS-CoV-2 vaccines in development. Nature 2020, 586, 516–527. [CrossRef] [PubMed]
7. Al-Sadeq, D.; Shurrab, F.; Ismail, A.; Amanullah, F.H.; Thomas, S.; Aldewik, N.; Yassine, H.M.; Rahim, H.A.; Abu-Raddad, L.J.; Nasrallah, G.K. Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals. J. Travel Med. 2021, 28, taab190. [CrossRef] [PubMed]
8. Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021, 27, 1205–1211. [CrossRef] [PubMed]
9. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D.R.; Bailey, M.J.; Mansour, M.; McMahon, M.; Meade, P.; Mendu, D.R.; Muellers, K.; et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020, 370, 1227–1230. [CrossRef]
10. Nasrallah, G.K.; Dargham, S.R.; Shurrab, F.; Al-Sadeq, D.W.; Al-Jighefee, H.; Chemaitelly, H.; Al Kanaani, Z.; Al Khal, A.; Al Kuwari, E.; Coyle, P. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci. Rep. 2021, 11, 1–10. [CrossRef]
11. Younes, S.; Al-Jighefee, H.; Shurrab, F.; Al-Sadeq, D.; Younes, N.; Dargham, S.; Al-Dewik, N.; Qotba, H.; Syed, M.; Alnuaimi, A.; et al. Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals. Microorganisms 2021, 9, 245. [CrossRef]
12. Ismail, A.; Shurrab, F.M.; Al-Jighefee, H.T.; Al-Sadeq, D.W.; Qotba, H.; Al-Shaar, I.A.; Yassine, H.M.; Abu-Raddad, L.J.; Nasrallah, G.K. Commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays. Front. Biosci. (Landmark Ed.) 2021, 26, 198–206. [CrossRef]
13. Anichini, G.; Terrosi, C.; Gandelino, C.; Gori Savellini, G.; Fabrizi, S.; Miceli, G.B.; Cusi, M.G. SARS-CoV-2 antibody response in persons with past natural infection. N. Engl. J. Med. 2021, 385, 90–92. [CrossRef]
14. Vicenti, I.; Basso, M.; Gatti, F.; Scagianti, R.; Boccuto, A.; Zago, D.; Molodo, E.; Dragoni, F.; Parisi, S.G.; Zazzi, M. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Int. J. Infect. Dis. 2021, 112, 40–44. [CrossRef]
15. Ebinger, J.E.; Fert-Bober, J.; Printsev, I.; Wu, M.; Sun, N.; Prostko, J.C.; Frias, E.C.; Stewart, J.L.; Van Eyk, J.E.; Braun, J.G.; et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 2021, 27, 981–984. [CrossRef]
16. Sokal, A.; Barba-Spaeth, G.; Fernández, I.; Broketa, M.; Azzaoui, I.; de La Selle, A.; Vandenberghe, A.; Fourati, S.; Roeser, A.; Meola, A.; et al. mRNA vaccination of naïve and COVID-19-infected individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 2021, 54, 2893–2907. [CrossRef]
17. Castro, A.; Ozturk, K.; Zanetti, M.; Carter, H. In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. PLoS ONE 2021, 16, e0264731. [CrossRef]
18. Tyner, H.L.; Thompson, M.G.; Burgess, J.L.; Grant, L.; Gaglani, M.; Kuntz, J.L.; Naleway, A.L.; Thornburg, N.J.; Caban-Martinez, A.J.; Yoon, S.K.; et al. Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection. medRxiv 2021. [CrossRef]
19. Ponticelli, D.; Antonazzo, I.C.; Caci, G.; Vitale, A.; Della Ragione, G.; Romano, M.L.; Borrelli, M.; Schiavone, B.; Polosa, R.; Ferrara, P. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. J. Travel Med. 2021, 28, asab173. [CrossRef]
20. Naaber, P.; Tserel, L.; Kangro, K.; Sepp, E.; Jüürjenson, V.; Adamson, A.; Haljasmägi, L.; Rumm, A.P.; Marustie, R.; Kärner, J.; et al. Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health-Eur. 2021, 10, 100208. [CrossRef]
21. Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 2021, 385, e84. [CrossRef]
22. Müller, L.; Andrä, M.; Moskorz, W.; Drexler, I.; Walotka, L.; Grothmann, R.; Ptak, J.; Hillebrandt, J.; Ritchie, A.; Rabl, D.; et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. medRxiv 2021.
24. Jalkanen, P.; Kolehmainen, P.; Häkkinen, H.; Huttenen, M.; Tähtinen, P.; Lundberg, R.; Maljanen, S.; Reinholm, A.; Tauriainen, S.; Pakkanen, S. COVID-19 mRNA vaccine induced antibody responses and neutralizing antibodies against three SARS-CoV-2 variants. Nat. Commun. 2021, 12, 3991. [CrossRef]

25. Abe, K.T.; Hu, Q.; Mozafarirashjin, M.; Samson, R.; Manguiat, K.; Robinson, A.; Rathod, B.; Wang, J.H.; Iskilova, M.; Pasculescu, A. Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers. medRxiv 2021.

26. Collier, D.A.; Ferreira, I.A.; Kotagiri, P.; Datir, R.P.; Lim, E.Y.; Touizer, E.; Meng, B.; Abdullahi, A.; Elmer, A.; Kingston, N.; et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 2021, 596, 417–422. [CrossRef]

27. Goel, R.R.; Painter, M.M.; Apostolidis, S.A.; Mathew, D.; Meng, W.; Rosenfeld, A.M.; Lundgreen, K.A.; Reynaldi, A.; Khoury, D.S.; Pattekar, A.; et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021, 374, abm0829. [CrossRef]